GU Cancers 2026 | BOND-003 cohort P: cretostimogene for BCG-unresponsive papillary NMIBC

So the BOND is an ongoing study in BCG on responsive disease. Most of the studies so far have concentrated on carcinoma in situ, CIS, with or without papillary disease. This is one of the few trials that is concentrating on this cohort P on papillary only disease, so no CIS. And that’s important because all the approved therapies thus far have been for patients with CIS with or without papillary disease. So their CIS had to be present. So this is more of a sort of adjuvant type setting. And so we have to look at it a little bit differently than the approved agents and all the results that we’ve seen in the past. So this cohort, P, again, P for papillary, those 56 patients that are being presented here, the outcomes, these are early outcomes, but they’re really highly encouraging using tadalafil is not correct, the correct term is a different medication, the medication is actually called “tigilimumogene tadenovec” given as an induction phase, and then followed by maintenance. And this maintenance is carried on every three months quarterly for a year and then carried on after that for up to three years. So the results that we’re presenting today is the six month and the nine month result. By six months, 85% of the patients were disease free and by nine months, 80% of the patients are disease free. So these are highly encouraging results and again a highly recurrent you know disease state where we’re seeing lots of recurrences. So ongoing trial obviously and we’re looking forward to further results.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.